PT3305785T - Derivado de pirido[3,4-d]pirimidina e seu sal farmaceuticamente aceitável - Google Patents
Derivado de pirido[3,4-d]pirimidina e seu sal farmaceuticamente aceitávelInfo
- Publication number
- PT3305785T PT3305785T PT16803266T PT16803266T PT3305785T PT 3305785 T PT3305785 T PT 3305785T PT 16803266 T PT16803266 T PT 16803266T PT 16803266 T PT16803266 T PT 16803266T PT 3305785 T PT3305785 T PT 3305785T
- Authority
- PT
- Portugal
- Prior art keywords
- pyrido
- pharmaceutically acceptable
- acceptable salt
- pyrimidine derivative
- pyrimidine
- Prior art date
Links
- 159000000016 pyrido[3,4-d]pyrimidines Chemical class 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015110684 | 2015-05-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3305785T true PT3305785T (pt) | 2021-10-13 |
Family
ID=57442335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT16803266T PT3305785T (pt) | 2015-05-29 | 2016-05-27 | Derivado de pirido[3,4-d]pirimidina e seu sal farmaceuticamente aceitável |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10124004B2 (pt) |
| EP (1) | EP3305785B1 (pt) |
| JP (1) | JP6400196B2 (pt) |
| KR (1) | KR102601320B1 (pt) |
| CN (1) | CN107614499B (pt) |
| AR (1) | AR104789A1 (pt) |
| AU (1) | AU2016272258B2 (pt) |
| CA (1) | CA2987019C (pt) |
| CL (1) | CL2017003032A1 (pt) |
| CO (1) | CO2017012067A2 (pt) |
| CY (1) | CY1124800T1 (pt) |
| DK (1) | DK3305785T3 (pt) |
| ES (1) | ES2893478T3 (pt) |
| HR (1) | HRP20211360T1 (pt) |
| HU (1) | HUE056996T2 (pt) |
| IL (1) | IL255488B (pt) |
| LT (1) | LT3305785T (pt) |
| MX (1) | MX378648B (pt) |
| MY (1) | MY192487A (pt) |
| PH (1) | PH12017502171B1 (pt) |
| PL (1) | PL3305785T3 (pt) |
| PT (1) | PT3305785T (pt) |
| RU (1) | RU2695337C2 (pt) |
| SA (1) | SA517390409B1 (pt) |
| SG (1) | SG11201709837RA (pt) |
| SI (1) | SI3305785T1 (pt) |
| TW (1) | TWI714590B (pt) |
| WO (1) | WO2016194831A1 (pt) |
| ZA (1) | ZA201707499B (pt) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3043561C (en) * | 2016-11-28 | 2025-03-11 | Teijin Pharma Limited | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF |
| PT3546456T (pt) * | 2016-11-28 | 2022-02-28 | Teijin Pharma Ltd | Cristal de derivado da pirido[3,4-d]pirimidina ou seu solvato |
| CN107337634B (zh) * | 2017-08-28 | 2019-07-09 | 新发药业有限公司 | 一种阿贝西利中间体化合物的制备方法 |
| JP7100125B2 (ja) | 2017-10-27 | 2022-07-12 | フレゼニウス・カビ・オンコロジー・リミテッド | リボシクリブおよびその塩の改善された調製のためのプロセス |
| WO2019126559A1 (en) | 2017-12-20 | 2019-06-27 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| CA3085366A1 (en) * | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| EP3865488A4 (en) | 2018-12-19 | 2021-12-22 | Keythera (Suzhou) Pharmaceuticals Co. Ltd. | MACROCYCLIC COMPOUND AS CDK INHIBITOR, METHOD OF MANUFACTURING AND MEDICAL USE |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| AR119493A1 (es) * | 2019-07-29 | 2021-12-22 | Servier Lab | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos |
| WO2022037592A1 (zh) * | 2020-08-17 | 2022-02-24 | 南京明德新药研发有限公司 | 嘧啶并环类化合物 |
| GB202018412D0 (en) * | 2020-11-23 | 2021-01-06 | Exscientia Ltd | Malt-1 modulators ii |
| TW202237585A (zh) | 2020-11-27 | 2022-10-01 | 瑞士商瑞森製藥公司 | Cdk抑制劑 |
| WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| CN116023367A (zh) * | 2021-10-25 | 2023-04-28 | 优领医药科技(香港)有限公司 | 含四氢呋喃多环类衍生物、其药学上可接受的盐及其制备方法和应用 |
| WO2023109959A1 (zh) * | 2021-12-16 | 2023-06-22 | 药捷安康(南京)科技股份有限公司 | Cdk9抑制剂及其用途 |
| CN116410189B (zh) * | 2021-12-30 | 2024-08-06 | 中国科学院上海药物研究所 | 一种嘧啶并吡啶类化合物及其药用组合物和应用 |
| WO2023155841A1 (zh) * | 2022-02-16 | 2023-08-24 | 南京明德新药研发有限公司 | 嘧啶并环类化合物的盐型、晶型 |
| WO2024020380A1 (en) * | 2022-07-18 | 2024-01-25 | Iambic Therapeutics, Inc. | Quinazoline compounds and methods of use |
| TW202509031A (zh) * | 2023-05-15 | 2025-03-01 | 美商阿列克希雅醫療公司 | Cdk抑制劑萘啶化合物 |
| WO2025070601A1 (ja) * | 2023-09-27 | 2025-04-03 | 帝人ファーマ株式会社 | 関節リウマチ治療薬 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL220952B1 (pl) * | 2002-01-22 | 2016-01-29 | Warner Lambert Co | 2-(Pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-ony |
| ATE412650T1 (de) | 2003-07-11 | 2008-11-15 | Warner Lambert Co | Isethionat salz eines selektiven cdk4 inhibitors |
| JPWO2006008874A1 (ja) * | 2004-05-21 | 2008-05-01 | 萬有製薬株式会社 | アミノチアゾ−ル骨格を有するCdk4、6選択的阻害剤 |
| PE20110419A1 (es) | 2008-08-22 | 2011-07-13 | Novartis Ag | Compuestos de pirrolo-pirimidina como inhibidores de cdk |
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| UY33226A (es) * | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
| GB201216017D0 (en) * | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
-
2016
- 2016-05-27 PT PT16803266T patent/PT3305785T/pt unknown
- 2016-05-27 PL PL16803266T patent/PL3305785T3/pl unknown
- 2016-05-27 AU AU2016272258A patent/AU2016272258B2/en active Active
- 2016-05-27 EP EP16803266.2A patent/EP3305785B1/en active Active
- 2016-05-27 AR ARP160101534A patent/AR104789A1/es active IP Right Grant
- 2016-05-27 SI SI201631322T patent/SI3305785T1/sl unknown
- 2016-05-27 CN CN201680033175.XA patent/CN107614499B/zh active Active
- 2016-05-27 WO PCT/JP2016/065770 patent/WO2016194831A1/ja not_active Ceased
- 2016-05-27 MY MYPI2017704377A patent/MY192487A/en unknown
- 2016-05-27 ES ES16803266T patent/ES2893478T3/es active Active
- 2016-05-27 KR KR1020177034478A patent/KR102601320B1/ko active Active
- 2016-05-27 US US15/577,802 patent/US10124004B2/en active Active
- 2016-05-27 SG SG11201709837RA patent/SG11201709837RA/en unknown
- 2016-05-27 MX MX2017015277A patent/MX378648B/es unknown
- 2016-05-27 HU HUE16803266A patent/HUE056996T2/hu unknown
- 2016-05-27 DK DK16803266.2T patent/DK3305785T3/da active
- 2016-05-27 JP JP2017521910A patent/JP6400196B2/ja active Active
- 2016-05-27 LT LTEPPCT/JP2016/065770T patent/LT3305785T/lt unknown
- 2016-05-27 CA CA2987019A patent/CA2987019C/en active Active
- 2016-05-27 RU RU2017141454A patent/RU2695337C2/ru active
- 2016-05-27 TW TW105116653A patent/TWI714590B/zh active
- 2016-05-27 HR HRP20211360TT patent/HRP20211360T1/hr unknown
-
2017
- 2017-11-06 ZA ZA2017/07499A patent/ZA201707499B/en unknown
- 2017-11-07 IL IL255488A patent/IL255488B/en active IP Right Grant
- 2017-11-25 SA SA517390409A patent/SA517390409B1/ar unknown
- 2017-11-28 CO CONC2017/0012067A patent/CO2017012067A2/es unknown
- 2017-11-29 CL CL2017003032A patent/CL2017003032A1/es unknown
- 2017-11-29 PH PH12017502171A patent/PH12017502171B1/en unknown
-
2021
- 2021-10-08 CY CY20211100878T patent/CY1124800T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL255488B (en) | Pyrido[4,3-di]pyrimidine derivative and its pharmaceutically acceptable salt | |
| ZA201905456B (en) | Pyrrolo[1,2-b]pyridazine derivatives | |
| ZA201902893B (en) | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | |
| IL246564A (en) | 3-aryl-1-heterocyclic-pyrazolo [4,3- d] pyrimidine derivatives and their use in the treatment of diseases | |
| PL3345907T3 (pl) | Związki pirazolo[3,4-d]pirymidynowe lub ich sole | |
| IL255775B (en) | A method for producing a derivative of h7-pyrrolo[3,2-d]pyrimidine and its intermediate | |
| HUE057549T2 (hu) | Imidazo[1,2-a]pirimidinszármazékok, eljárás elõállításukra és alkalmazásaik | |
| EP3173412A4 (en) | 2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof | |
| EP3102036A4 (en) | 3-substituted carbonyl-naphtho[2,3-b]furane derivative or pharmaceutically acceptable salt thereof | |
| ZA201606794B (en) | 1,2-dihydro-3h-pyrrolo[1,2-c]imidazol-3-one derivatives and their use as antibacterial agents | |
| PL3395817T3 (pl) | Analog pirydo[1,2-a]pirymidonu, jego krystaliczna postać, jego związek pośredni i sposób jego wytwarzania | |
| EP3287459A4 (en) | Purinyl-n-hydroxyl pyrimidine formamide derivatives, preparation method therefor and use thereof | |
| EP3235816A4 (en) | 2-morpholin-4,6-disubstituted pyrimidine derivative, and preparation method and pharmaceutical use thereof | |
| GB201522532D0 (en) | Novel pyrrolo[3,2-c]pyridine-6-amino derivatives | |
| ZA201902828B (en) | Crystal of pyrido[3, 4-d]pyrimidine derivative or solvate thereof | |
| IL253427B (en) | The result of pyrazolo[3,4-d]pyrimidine and its use in the treatment of Jericho rose | |
| HUE050298T2 (hu) | Pirazolo[3,4-D]pirimidin vegyületek vagy annak sói | |
| HK1233254A1 (en) | 1,2-dihydro-3h-pyrrolo[1,2-c]imidazol-3-one derivatives and their use as antibacterial agents |